Cefoperazone Sodium
FDA-approved product (injectable, injection), marketed as Cefobid, Cefobid In Plastic Container.
- Registered studies
- 16
- Lab records
- 5
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Third-generation cephalosporins
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01DD12
Repurposing investigation
Cefoperazone Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA64.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli94.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae98.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
16registered studies name this medicine, for any condition. See them below.
Experimental
- E. coli: measured active in 1 of 1 lab record
- K. pneumoniae: measured active in 2 of 4 lab records
Show the 5 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cefoperazone Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more53.9% AI-predicted activityagainst E. coli50+ registered studies
- UbrogepantExisting use: Migraine disorder53.8% AI-predicted activityagainst E. coli24 registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more53.7% AI-predicted activityagainst E. coli50+ registered studies
- OdevixibatExisting use: Intrahepatic cholestasis53.7% AI-predicted activityagainst E. coli13 registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more53.6% AI-predicted activityagainst E. coli50+ registered studies
- SiponimodExisting use: Multiple sclerosis53.6% AI-predicted activityagainst E. coli33 registered studies
- LonafarnibExisting use: Hutchinson-Gilford progeria syndrome, Laminopathies, Progeria53.6% AI-predicted activityagainst E. coli39 registered studies
- Brilliant Blue GExisting use: Disclosing Agent53.4% AI-predicted activityagainst E. coli10 registered studies
- AbarelixExisting use: Neoplasm53.4% AI-predicted activityagainst E. coli5 registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more53.3% AI-predicted activityagainst E. coli50+ registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection53.2% AI-predicted activityagainst E. coliNo documented evidence found
- Ergotamine TartrateExisting use: Headache, Migraine disorder53.1% AI-predicted activityagainst E. coli10 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections
NCT00360607 · start 2004-07
Registered record
- Registry ID
- NCT00360607
- Conditions
- Infection
- Interventions
- Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.; Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited; Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.; Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-07
- Completion
- 2005-04
- Enrolment
- 307
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfectionInterventionMagnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.; Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited; Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.; Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.PhasePhase 4Registry statusCompleted